Huntington's Disease Cure Roadmap

Huntington's Disease Cure Roadmap

Overview

This roadmap outlines the path from current standard of care to disease modification and ultimately cure for Huntington's disease (HD). HD is a monogenic autosomal-dominant neurodegenerative disorder caused by CAG repeat expansion in the HTT gene, leading to mutant huntingtin (mHTT) protein with toxic gain-of-function properties. Unlike AD and PD, HD has a clearly defined genetic cause, enabling direct targeting of the underlying genetic driver. The challenge lies in effectively lowering mHTT throughout the CNS and addressing downstream pathology.

Huntington's Disease Cure Roadmap

Overview

This roadmap outlines the path from current standard of care to disease modification and ultimately cure for Huntington's disease (HD). HD is a monogenic autosomal-dominant neurodegenerative disorder caused by CAG repeat expansion in the HTT gene, leading to mutant huntingtin (mHTT) protein with toxic gain-of-function properties. Unlike AD and PD, HD has a clearly defined genetic cause, enabling direct targeting of the underlying genetic driver. The challenge lies in effectively lowering mHTT throughout the CNS and addressing downstream pathology.

Related: [Huntington's Disease](/diseases/huntingtons) | [Huntington's Knowledge Gaps](/gaps/huntingtons) | [AD Cure Roadmap](/mechanisms/ad-cure-roadmap) | [PD Cure Roadmap](/mechanisms/pd-cure-roadmap) | [Experiment Priority Index](/experiments/experiment-priority-index)

Phase 1: Diagnosis Confirmation and Symptomatic Management (NOW)

Goal: Accurate genetic diagnosis, symptom optimization, biomarker baseline

| Action | Status | Timeline |
|--------|--------|----------|
| Confirmatory genetic testing (CAG repeat) | Available | Week 1 |
| Baseline neurological exam + UHDRS | Standard of care | Week 1-2 |
| Blood biomarker panel (NfL, p-tau217, GFAP) | Available | Week 1 |
| Brain MRI (volumetrics, caudate/putamen) | Available | Week 1-2 |
| Cognitive testing (CAP-INTERNIST, SDMT) | Standard of care | Week 2 |
| Psychiatric evaluation | Standard of care | Week 2 |
| Tetrabenazine/Deutetrabenazine for chorea | FDA approved | Ongoing |
| Antipsychotics for behavioral symptoms | Off-label | Ongoing |
| Exercise program (150+ min/week) | Strong evidence | Ongoing |
| Multidisciplinary care (neurology, psychiatry, PT, OT, speech) | Standard of care | Ongoing |

Understanding gaps at this phase:

• What determines progression rate (CAG vs other modifiers)?
• Can NfL trajectory predict functional decline?
• When is the optimal time to initiate mHTT-lowering therapy?

Phase 2: Disease Modification Trials (2025-2028)

Goal: Lower mHTT protein throughout the CNS to slow or halt disease progression

ASO-Based mHTT Lowering

| Agent | Company | Mechanism | Trial Status | Expected Data |
|-------|---------|-----------|--------------|---------------|
| Tominersen (RG6042) | Roche/Ionis | ASO - all HTT mRNA | Phase 3 GENERATION-HD1 (completed) | Mixed - target engagement achieved but no clinical benefit in manifest patients[@kieburtz2023] |
| Tominersen (lower dose) | Roche/Ionis | ASO - all HTT | Phase 2 (exploring lower dose) | 2026 |
| Other HTT-ASOs | Various | allele-selective | Preclinical/Phase 1 | 2027+ |

Key learnings from tominersen:

• Target engagement was robust (70%+ mHTT reduction in CSF)
• Clinical benefit was not observed, possibly due to:
• Treatment started too late (manifest disease)
• Off-target effects from lowering wild-type HTT
• Insufficient CNS distribution
• Need for combination approach

Gene Therapy Approaches

| Approach | Vector | Mechanism | Status | Timeline |
|----------|--------|-----------|--------|----------|
| AAV-HTT-ASO | AAV9 | CNS-delivered ASO | IND-enabling | 2026-2027 |
| AAV-miRNA | AAV9/AAV10 | Non-coding RNA silencing | Preclinical | 2027+ |
| CRISPR-based | Various | Gene editing | Preclinical | 2028+ |
| Antisense Villages | AAV-PHP.B | Wild-type sparing | Preclinical | 2028+ |

Critical experiments needed:

• Does allele-selective mHTT lowering provide better safety/efficacy?
• What is the optimal timing for intervention (premanifest vs manifest)?
• Can CSF mHTT serve as a surrogate endpoint?
• What combination approaches work best (ASO + small molecule)?

Small Molecule Approaches

| Approach | Target | Status | Timeline |
|----------|--------|--------|----------|
| HTT aggregation inhibitors | mHTT aggregation | High-throughput screening | 2027+ |
| Autophagy enhancers | mHTT clearance | Phase 1/2 | 2026-2027 |
| Epigenetic modulators | Transcriptional dysregulation | Preclinical | 2027+[@sanchez2024] |
| BDNF mimetics | Synaptic function | Preclinical | 2028+ |

Understanding gaps:

• What is the most toxic mHTT species (full-length, fragments, oligomers)?
• Can wild-type HTT function be preserved while lowering mHTT?
• Does mHTT lowering affect peripheral organs?

Phase 3: Combination Therapy and Precision Medicine (2027-2030)

Goal: Multi-target intervention tailored to individual patient biology

Rationale for Combination

Given HD's complex pathophysiology, combining mHTT lowering with downstream targets may provide synergistic benefit:

| Combination | Rationale | Status |
|-------------|-----------|--------|
| mHTT-ASO + autophagy enhancer | Lower production + increase clearance | Preclinical |
| mHTT-ASO + epigenetic modulator | Lower mHTT + restore transcriptional patterns | Preclinical |
| mHTT-ASO + neurotrophic support | Protect remaining neurons | Conceptual |
| mHTT-ASO + neuroinflammation target | Address microglial activation | Preclinical |

Precision Medicine Requirements

Biomarker-guided patient selection:

• NfL trajectory for progression prediction
• CSF mHTT for target engagement
• Genetic modifiers (CAG, BDNF, DNA repair genes)
• PET markers for mHTT aggregation (in development)

• Platform trials for rare diseases
• Adaptive designs for efficient dose-finding
• Premanifest patient enrollment
• Digital endpoints (wearables, smartphone)

• Which biomarkers predict treatment response?
• What is the optimal therapeutic window?
• Can we identify rapid vs slow progressors early?

Phase 4: Regenerative and Restorative Approaches (2028-2035)

Goal: Replace lost neurons and restore function

| Approach | Status | Mechanism | Timeline |
|----------|--------|-----------|----------|
| iPSC-based cell therapy | Preclinical | Striatal neuron replacement | 2030+ |
| In vivo neuronal reprogramming | Preclinical | Convert glia to neurons | 2030+ |
| Mitochondrial transplantation | Phase 1 (stroke) | Restore cellular energy | HD trials 2028+ |
| Gene therapy for BDNF delivery | Preclinical | Neurotrophic support | 2028+ |
| Exosome-based delivery | Preclinical | BBB-penetrant delivery | 2028+ |

Critical experiments needed:

• Will transplanted neurons survive in mHTT-toxic environment?
• Can we combine mHTT lowering with cell therapy?
• What is the optimal delivery route for cell replacement?

Phase 5: Prevention and Pre-Symptomatic Intervention (2030+)

Goal: Identify and treat individuals before symptom onset

| Approach | Status | Timeline |
|----------|--------|----------|
| Genetic testing for at-risk individuals | Available | Now |
| Premanifest natural history studies | Ongoing | 2025-2030 |
| Early biomarker detection | In development | 2027+ |
| Pre-symptomatic mHTT lowering | Pending trial design | 2030+ |
| Population-wide genetic screening | Ethical framework needed | 2035+ |

Understanding gaps:

• What is the earliest detectable biomarker change?
• How do genetic modifiers (CAG, other) affect premanifest progression?
• What ethical framework is needed for pre-symptomatic treatment?

Biomarkers for HD Clinical Trials

Fluid Biomarkers

| Biomarker | Type | Clinical Utility | Status |
|-----------|------|------------------|--------|
| mHTT protein (CSF) | Direct | Target engagement, dose selection | Validated[@tabrizi2023] |
| NfL | Axonal injury | Progression, treatment response | Validated[@troncoso2023] |
| p-tau217 | Tau pathology | Disease staging | In development |
| GFAP | Astrocyte activation | Progression | In development |
| Neurofilament heavy (NfH) | Axonal injury | Progression marker | In development |

Imaging Biomarkers

| Modality | Target | Clinical Utility | Status |
|----------|--------|------------------|--------|
| MRI (volumetry) | Caudate, putamen volume | Progression, treatment response | Standard |
| Diffusion tensor imaging | White matter integrity | Disease staging | Research |
| PET (mHTT tracer) | mHTT aggregates | Target engagement | In development |
| PET (TSPO) | Microglial activation | Neuroinflammation | Research |

Digital Biomarkers

| Type | Target | Status |
|------|--------|--------|
| Wearable accelerometers | Chorea, gait, activity | Validation |
| Smartphone-based | Cognitive, speech | Validation |
| Digital timed up-and-go | Motor function | Validation |

Clinical Trials Landscape

Active/Recruiting Trials

| Trial | Phase | Intervention | Population | Status |
|-------|-------|--------------|------------|--------|
| PRECODE | Natural history | N/A | Premanifest HD | Recruiting |
| HDClarity | Biomarker | N/A | Manifest HD | Recruiting |
| Various | Phase 1/2 | Autophagy enhancers | Manifest HD | Various |

Completed Trials (Key Learnings)

| Trial | Intervention | Key Finding |
|-------|--------------|-------------|
| GENERATION-HD1 | Tominersen 120mg | Robust target engagement, no clinical benefit in manifest |
| SIGNAL | RG6042 | Safety confirmed in premanifest |

Research Gaps Addressed by This Roadmap

| Gap | Addressed in Phase | Solution |
|-----|-------------------|----------|
| mHTT clearance mechanisms | Phase 2-3 | ASO + small molecule combinations |
| Biomarker development | Phase 1-2 | NfL, mHTT, imaging endpoints |
| Timing of intervention | Phase 2-3 | Premanifest trials |
| Gene therapy delivery | Phase 2-3 | AAV vectors, novel routes |
| Striatal vulnerability | Phase 3-4 | Cell therapy, targeted delivery |
| Epigenetic dysregulation | Phase 3 | Epigenetic modulators |
| Microglial contributions | Phase 3 | Anti-inflammatory combinations |

See Also

• [Huntington's Disease](/diseases/huntingtons)
• [Huntington's Knowledge Gaps](/gaps/huntingtons)
• [Huntington's Biomarkers and Precision Therapy](/mechanisms/huntingtons-biomarkers-and-precision-therapy)
• [Huntington's Disease Pathway](/mechanisms/huntingtons-disease-pathway)
• [Tominersen](/therapeutics/tominersen-huntingtons)
• [Antisense Oligigonucleotide Therapy](/technologies/antisense-oligonucleotides)
• [Experiment Priority Index](/experiments/experiment-priority-index)
• [Novel Therapy Index](/ideas/novel-therapy-index)